RMO No. 23-2020 centralizes ATRIG processing for VAT-exempt imported prescription drugs and medicines and confirms key exemption dates.
Importers, manufacturers, distributors, wholesalers, and retailers dealing in VAT-exempt prescription drugs and medicines must secure the proper Authority to Release Imported Goods before release of covered importations. RMO No. 23-2020 centralizes the processing of ATRIG applications for VAT-exempt imported prescription drugs and medicines with Revenue District Office No. 33 β Intramuros-Ermita-Malate, and confirms the effective dates for the VAT exemption under Republic Act No. 11467 and Revenue Regulations No. 18-2020.
What RMO No. 23-2020 Changes
RMO No. 23-2020 clarifies how the VAT exemption on the sale and importation of certain prescription drugs and medicines is implemented at the importation stage. The key compliance point is the issuance of an Authority to Release Imported Goods, or ATRIG, for importations of articles that are exempt from VAT.
The issuance is important because VAT exemption on importation is not merely a pricing or invoicing matter. For covered imported drugs and medicines, the importer must deal with the ATRIG requirement before release of goods. Without proper processing, a shipment may face release issues, customs clearance delays, or VAT treatment inconsistent with the exemption contemplated under Section 109(AA) of the National Internal Revenue Code, as amended by Republic Act No. 11467 and implemented by Revenue Regulations No. 18-2020.
The most important administrative change is that Revenue District Office No. 33 β Intramuros-Ermita-Malate, under Revenue Region No. 6 β Manila, is the office tasked to process ATRIG applications for covered VAT-exempt importations. RMO No. 23-2020 states that, for consistency and uniformity in the issuance of ATRIGs for VAT-exempt transactions, this RDO shall process applications filed by manufacturers, distributors, wholesalers, and retailers of covered drugs and medicines.
Prescription Drugs and Medicines Covered by the VAT Exemption
The VAT exemption under RMO No. 23-2020 covers prescription drugs and medicines for specific diseases and conditions. The first group consists of prescription drugs and medicines for diabetes, high cholesterol, and hypertension. The second group consists of prescription drugs and medicines for cancer, mental illness, tuberculosis, and kidney diseases.
For businesses searching for the applicable BIR rule on VAT-exempt prescription drugs Philippines, VAT exemption on imported medicines, ATRIG for imported drugs, and BIR RMO 23-2020 medicines VAT exemption, the practical point is that the exemption is condition-specific and date-specific. It does not automatically cover all medicines or all pharmaceutical products. The medicines must fall within the covered categories and must be included in the list of approved drugs and medicines issued by the Department of Health.
RMO No. 23-2020 expressly refers to manufacturers, distributors, wholesalers, and retailers of drugs and medicines included in the Department of Health list of approved drugs and medicines. This makes the DOH list a central compliance reference. Businesses should not treat the VAT exemption as applicable merely because a product is a prescription drug; they should verify whether the product is within the covered categories and appears in the applicable DOH-approved list.
Effective Dates Businesses Must Track
RMO No. 23-2020 identifies two separate effectivity dates for the VAT exemption, depending on the type of prescription drug or medicine involved.
For prescription drugs and medicines for diabetes, high cholesterol, and hypertension, the exemption applies beginning January 27, 2020. The issuance notes that the effectivity of Republic Act No. 11467 was clarified under Revenue Memorandum Circular No. 65-2020 as taking effect immediately after its complete publication in a newspaper of general circulation pursuant to Section 15 of Republic Act No. 11467, or on January 27, 2020.
For prescription drugs and medicines for cancer, mental illness, tuberculosis, and kidney diseases, the exemption applies beginning January 1, 2023.
These dates matter for importers and accounting teams because VAT treatment depends not only on the nature of the drug but also on the date when the statutory exemption became applicable to that category. For diabetes, high cholesterol, and hypertension medicines, businesses should review transactions beginning January 27, 2020. For cancer, mental illness, tuberculosis, and kidney disease medicines, businesses should track the later date of January 1, 2023.
Who Is Most Affected by RMO No. 23-2020
The businesses most directly affected are pharmaceutical importers and companies in the medicine supply chain. This includes manufacturers importing raw or finished covered medicines, distributors bringing in covered prescription drugs, wholesalers handling imported VAT-exempt medicines, and retailers whose inventory includes covered prescription drugs and medicines.
Corporate accountants, tax managers, customs brokers, and supply chain teams are also affected because the rule sits at the intersection of VAT compliance, importation documentation, and product classification. A company may have a valid commercial reason to claim VAT exemption, but if its importation documents, ATRIG application, and supporting DOH references are incomplete or inconsistent, the release and tax treatment of the goods may become problematic.
Hospitals, pharmacies, health product companies, and pharmaceutical distribution groups should also take note, especially if they import or source medicines from importers who rely on VAT exemption. Although RMO No. 23-2020 is framed as an internal revenue order for BIR officers and concerned parties, its effect is practical and commercial: businesses must know where and how the ATRIG application is processed for VAT-exempt imported prescription drugs and medicines.
Key ATRIG Compliance Requirement
For VAT purposes, the ATRIG must be issued on importations of articles exempt from VAT pursuant to the existing ATRIG framework under RMO No. 35-2002 dated October 28, 2002. RMO No. 23-2020 does not replace the ATRIG procedures under RMO No. 35-2002. Instead, it states that the policies, guidelines, and procedures set forth in RMO No. 35-2002 shall be strictly followed and observed.
This means covered taxpayers should prepare their ATRIG applications in accordance with the existing BIR requirements for VAT-exempt importations, while ensuring that the application is processed through Revenue District Office No. 33 β Intramuros-Ermita-Malate. The orderβs emphasis on consistency and uniformity indicates that the BIR intended a single processing point for these applications rather than varying treatment across offices.
For companies handling multiple shipments, the compliance workflow should be built into import planning. The finance, logistics, customs brokerage, and regulatory teams should coordinate before arrival or release of goods. Waiting until the shipment is already pending release can create avoidable delays, especially if the company still needs to confirm DOH listing, product category, and the correct effectivity date.
Penalties and Risks for Non-Compliance
RMO No. 23-2020 does not prescribe a new specific penalty amount for failure to comply with the ATRIG process for covered imported prescription drugs and medicines. However, the practical risks are significant. Failure to secure or properly process the ATRIG may result in difficulty claiming VAT exemption at importation, delay in release of imported goods, and potential disputes on the correct VAT treatment of the transaction.
Businesses should also remember that VAT exemption claims are usually documentation-driven. If a taxpayer treats a product as VAT-exempt without the necessary support, the company may face assessment risk, audit exposure, or disallowance of the claimed VAT-exempt treatment. For pharmaceutical businesses, the commercial consequences may include shipment delays, inventory disruption, and unexpected tax costs that affect pricing and margins.
Practical Steps for Pharmaceutical Importers and Medicine Businesses
First, identify whether the imported product is a prescription drug or medicine for diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, or kidney diseases. The category determines whether the relevant effectivity date is January 27, 2020 or January 1, 2023.
Second, verify whether the drug or medicine is included in the list of approved drugs and medicines issued by the Department of Health. RMO No. 23-2020 specifically refers to manufacturers, distributors, wholesalers, and retailers of drugs and medicines included in the DOH list, so this verification should be part of the companyβs import file.
Third, process the ATRIG application through Revenue District Office No. 33 β Intramuros-Ermita-Malate, Revenue Region No. 6 β Manila. Internal teams and customs brokers should be aligned on this processing office to avoid misfiling or delay.
Fourth, follow the policies, guidelines, and procedures under RMO No. 35-2002. RMO No. 23-2020 confirms that the earlier ATRIG rules remain the procedural framework for VAT-exempt importations.
Fifth, maintain a complete compliance file for each importation. The file should support the product classification, DOH listing, effectivity date, VAT-exempt basis, ATRIG application, and importation documents. This is especially important for companies that may later need to explain the VAT treatment during BIR examination, customs review, or internal audit.
How Ablola, Saribong & Gueco Can Help
RMO No. 23-2020 is a short issuance, but it has a direct operational impact on importers and pharmaceutical businesses claiming VAT exemption on covered prescription drugs and medicines. The risk is not only legal; it is also logistical. A wrong assumption on coverage, filing office, effectivity date, or supporting documentation can disrupt importation and create tax exposure.
Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT exemption review, ATRIG documentation, importation tax issues, and tax audit risk management. For pharmaceutical importers, distributors, wholesalers, retailers, and companies dealing with VAT-exempt medicines, our team can help review product coverage, documentation, and practical compliance steps under RMO No. 23-2020, RMO No. 35-2002, Revenue Regulations No. 18-2020, and related BIR issuances.
For guidance on VAT-exempt imported medicines, ATRIG applications, BIR compliance, and Philippine tax issues affecting your business, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.